AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06575894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Facilitation
Description: Home visiting supervisor trained in adapted facilitation will employ interactive problem-solving focused on supporting the home visitors to implement Mothers and Babies - working with pregnant people, challenges with resources, additional training needs, etc. - based on understanding the individual communities, contexts, and recipients' and home visitors' needs over the course of the project.
Study NCT06575894 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Implementation
Description: Standard Mothers and Babies training includes ongoing implementation support from the Mothers and Babies training team
Study NCT05388695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
Description: Single or sequential injection of CD19, CD20 and CD22 CAR T cells.
Study NCT05473897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catalyst Cryohelmet
Description: The Catalyst Cryohelmet will be used to provide head and neck cooling. It comes in three sizes based on head circumference. Once informed consent is obtained then the patient's head will be measured to provide the correct helmet size. The Cold Packs will be stored in the emergency department freezer and applied to the helmet once the helmet is ready to be applied. The Cryohelmet will be washed between uses. The Catalyst Cryohelmet is registered with the FDA as D344812. It is a Class I (minimal risk) device not requiring pre-marketing or regulatory processes.
Study NCT06492304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX131
Description: CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
Study NCT05804942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High glycemic index
Description: Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:>70), 20% fat and 20% protein.
Study NCT05804942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium glycemic index
Description: Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:55-70), 20% fat and 20% protein.
Study NCT05595720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hight intenisty laser
Description: 7W(LAZR-207)/15W(LAZR-215\&115)HIGH POWER LASER THERAPYUNIT WITH 2 WAVELENGTHMODES,COMBINATION(810+980 NM) AND SINGLE(1064 NM)
Study NCT05198453 — intervention group
Intervention type: BIOLOGICAL
Intervention: vaccination
Description: patients who received COVID-19 vaccine
Study NCT05804942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low glycemic index
Description: Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:\<55), 20% fat and 20% protein.
Study NCT04518553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active comarator using antiviral drug of nucleoside analogues
Description: using antiviral drug of nucleoside analogues without additional active interference to control Hepatitis B virus.
Study NCT04518553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA+purification
Description: Based on antiviral drug of nucleoside analogues, plasma purification is added to control hepatitis B virus every three months. After three months, plasma purification will continue if hepatitis B virus DNA titer is still higher than cut-off normal value. plasma purification process lasts 2.5-3 hours each session.
Study NCT05735028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centipeda minima+PD-1/PD-L1 inhibitor
Description: Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
Study NCT05735028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1/PD-L1 inhibitor
Description: PD-1/PD-L1 inhibitor
Study NCT04729101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Oral tablet
Study NCT04729101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Oral capsule
Study NCT05327439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine (electronic cigarette)
Description: Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at in-person and phone assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose one of two e-liquid flavors (tobacco, menthol) at baseline.
Study NCT05327439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine (nicotine pouch)
Description: Participants will be provided with 4mg nicotine pouches for 8 weeks and encouraged at in-person and phone assessments to use the nicotine pouches any time they would normally smoke. Participants will be able to choose one of two nicotine pouch flavors (tobacco, mint) at baseline.
Study NCT06426082 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Thermoneutral condition
Description: Participants will be exposed 2 hours/day at 32ºC for 5 days/week
Study NCT06426082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold condition
Description: Participants will be exposed 2 hours/day at 18ºC for 5 days/week
Study NCT05430022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism-adapted Group Cognitive Behavioral Therapy
Description: The autism-adapted Group Cognitive Behavioral Therapy (CBT) was designed by the PI and research team in collaboration with autistic stakeholders (i.e., adults, parents, researchers). It is a 12-week group intervention (90 min) delivered on a weekly basis in an outpatient psychiatry clinic by licensed clinical psychologists and psychology trainees. Each group is comprised of 8-9 autistic adolescents (11-17 years old; middle and high school) with depression. The intervention targets adolescents' perception and understanding of self, including autistic identity, through a series of cognitive-behavioral approaches including psychoeducation, emotion regulation, cognitive distortions, cognitive restructuring, behavioral rehearsals, and weekly homework assignments.
Study NCT06190379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential oil blend
Description: an aroma stick containing a blend of essential oils
Study NCT06190379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an aroma stick containing an inert blend of oils
Study NCT06326541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Listening to the Holy Quran.
Study NCT06068192 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04816721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Oral suspension
Study NCT04816721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension to match EDP-938
Study NCT06414408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Pill
Description: 200mg Dose
Study NCT06426082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise condition
Description: Participants will perform aerobic exercise training 5 days/week at 65% heart rate reserve for 60 minutes each training session
Study NCT04098666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablet identical to metformin, up to 4 tablets a day
Study NCT04098666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release metformin
Description: Metformin extended release 500 mg tablets, up to 4 tablets a day
Study NCT06252636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A2 Milk
Description: Cow's milk that contains only A2 β-Casein.
Study NCT06252636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: A1/A2 Milk
Description: Cow's milk that contains both A1 β-Casein and A2 β-Casein.
Study NCT05230459 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AB-1003 dose level 1
Description: Single intravenous infusion of AB-1003 gene therapy at dose level 1
Study NCT05230459 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AB-1003 dose level 2
Description: Single intravenous infusion of AB-1003 gene therapy at dose level 2
Study NCT05230459 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous infusion of Placebo
Study NCT06426082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Participants will take salbutamol 12 mg/day. 7 days week
Study NCT04926376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye90 Microspheres
Description: Y90 glass microspheres
Study NCT06643845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroplasty
Description: In the surgery arm, patients will have their surgery (arthroplasty), as originally planned.
Study NCT06643845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical and non-medical treatments
Description: In the medical care arm, patients will follow multimodal medical strategies to prevent surgery in a population of patients with knee osteoarthritis having a first indication of knee prosthesis
Study NCT04893226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding (TRF)
Description: Subjects will be educated about the health benefits of time-restricted feeding (TRF). Each subject in the TRF group will self-select a 10 hour (10h +/- 1hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily meals for the duration of the study.
Study NCT06642818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protocolized interview and prevention messages
Description: This care consists of a consultation carried out by an environmental health expert (midwife, environmental health engineer) from the PREVENIR platforms. This consultation is carried out through a protocolized interview already developed which allows the identification of exposure to risk factors on reproduction. During the interview, prevention messages targeted at the exposures identified during the interview are delivered.
Study NCT06016907 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet-delivered cognitive behavioral therapy (ICBT)
Description: Cognitive behavioral therapy (CBT) delivered through an internet platform with therapist support.
Study NCT06016907 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-person cognitive behavioral therapy (CBT)
Description: Cognitive behavioral therapy (CBT) delivered in-person at a clinic by a therapist.
Study NCT06588218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watermelon
Description: 2.5 cups of whole fresh watermelon (\~375 grams, 115 kcals, 0.5g fat, 1.5g fiber, 17,225mcg lycopene, 30.75mg vitamin C) of fresh watermelon daily for six weeks
Study NCT06588218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Belvita Breakfast Sandwich + 12 oz Water
Description: Belvita breakfast sandwich; 115 kcals, 1.5g fiber, 4.5g fat, 0mg lycopene, 0mg vitamin C) as well as 12 ounces of water
Study NCT05218161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine alone
Description: All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
Study NCT05218161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine alone
Description: All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
Study NCT06602063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery/chemotherapy
Description: secondary cytoreductive surgery followed by 6 cycles of post-operative chemotherapy
Study NCT06602063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administered at a fixed dose of 200 mg IV every 21 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity or withdrawal of consent.
Study NCT05324332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-P16-093
Description: Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
Study NCT06418763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Baobab spread mixed with fermented brown seaweed
Description: 5-day intake period
Study NCT06418763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Baobab spread
Description: 5-day intake period
Study NCT05324332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
Study NCT04175054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body-weight supported treadmill training in a room cooled to 16°C
Description: Exercise will be performed on a treadmill using an overhead harness for safety in a temperature controlled-room at 16°C with 1:1 supervision. The high intensity group will maintain vigorous intensity with a target workload >60% of heart rate reserve for 30 min (plus 5min warm up and 5min cool down) while the low-intensity group will walk at mild intensity (\<40% heart rate reserve) for the same duration. Heart rate, blood pressure, and rating of perceived exertion will be recorded throughout to monitor for potential adverse events and to ensure that target training zone heart rates are maintained. The intervention is 3 times per week for 12 weeks, with a 3-month run-in observational period to confirm disease stability, and 3-month follow-up to determine the sustainability of effects.
Study NCT04175054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training in a room cooled to 16°C
Description: Exercise will be performed on a treadmill using an overhead harness for safety in a temperature controlled-room at 16°C with 1:1 supervision. The high intensity group will maintain vigorous intensity with a target workload >60% of heart rate reserve for 30 min (plus 5min warm up and 5min cool down) while the low-intensity group will walk at mild intensity (\<40% heart rate reserve) for the same duration. Heart rate, blood pressure, and rating of perceived exertion will be recorded throughout to monitor for potential adverse events and to ensure that target training zone heart rates are maintained. The intervention is 3 times per week for 12 weeks, with a 3-month run-in observational period to confirm disease stability, and 3-month follow-up to determine the sustainability of effects.
Study NCT06383598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: All study participants will undergo one 18F-FDG PET/CT scan.
Study NCT05392764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: once-daily oral empagliflozin 10 mg
Study NCT05392764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching empagliflozin 10 mg
Study NCT06032923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: The dietary supplement Nicotinamide Riboside or a placebo capsule in subjects with SLE. Niagen(R) is a commercially available form of nicotinamide riboside (NR)
Study NCT06281171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkillTalk for Autistic Young Adults
Description: A Microskills video training library on communication skills for autistic young adults.
Study NCT06281171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flyer Library
Description: A collection of existing online resources on relationship skills
Study NCT06032923 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nicotinamide Riboside
Description: The dietary supplement Nicotinamide Riboside or a placebo capsule in subjects with SLE. Niagen(R) is a commercially available form of nicotinamide riboside (NR)
Study NCT06581926 — intervention group
Intervention type: OTHER
Intervention: Behavioral assessment
Description: nutrition knowledge reward-related eating body awareness
Study NCT06528496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DANYELZA
Description: DANYELZA is a humanized monoclonal antibody of the IgG1 subclass
Study NCT06528496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Yeast derived recombinant human Sargramostim (GM-CSF)
Study NCT06528496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Cyclophosphamide is an alkylating agent related to nitrogen mustard
Study NCT06528496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan is a topoisomerase I-inhibitor that is a semisynthetic derivative of camptothecin.
Study NCT06528496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine is an alkaloid isolated from Vinca rosea Linn (periwinkle).
Study NCT06528496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is an anthracycline antibiotic
Study NCT06528496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide is a structural analogue of cyclophosphamide
Study NCT06528496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide for Injection is available as a 20 mg/mL solution in sterile multiple dose vials (5 mL, 25 mL, or 50 mL each).
Study NCT06528496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is available in 50 mg, 150 mg, 450 mg, and 600 mg vials.
Study NCT06528496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan hydrochloride trihydrate (CPT-11) is a topoisomerase I inhibitor
Study NCT06528496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is administered intravenously
Study NCT05504694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: The enrolled patients will receive ofatumumab (20 mg/0.4 ml) subcutaneously administered at baseline, Day 7, Day 14 and monthly thereafter. Patients will receive ofatumumab therapy for a total of 48 weeks.~The first 4 infusions will be administered at study center site; subsequent infusions will be given in the patient's home with a nurse online interview to administer the infusion.
Study NCT06108492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2005
Description: In dose Escalation: Four dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period.~In indication Expansion: Indications will be selected to evaluate preliminary efficacy.
Study NCT06055556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Heart Transplantation
Description: Partial heart transplantation involves surgical replacement of the semilunar heart valve with a fresh donor graft. The surgical procedure (homograft valve replacement) is common and standard of care. The investigational aspect of this is using a freshly procured valve rather than a cryopreserved, cadaveric one and also the use of limited immunosuppression to help maintain the freshly procured valve as living tissue.
Study NCT06055556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freshly procured valve
Description: Fresh donor graft semilunar heart valve.
Study NCT06120582 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-002, dose 1
Description: Adeno-associated viral vector carrying the FIX gene single infusion at dose 1.
Study NCT06120582 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-002, dose 2
Description: Adeno-associated viral vector carrying the FIX gene single infusion at dose 2.
Study NCT06120582 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-002, dose 3
Description: Adeno-associated viral vector carrying the FIX gene single infusion at dose 3.
Study NCT06463171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib, dosing regimen: 110mg/day orally, once daily in a 28-day cycle, continuously.~Lastet, dosing regimen: 50 mg/day orally, every 28 days in a cycle, two weeks of continuous oral administration, two weeks off.
Study NCT06099821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
Study NCT06586190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Floor Pedal Bike with Guided Instructions for Home
Description: Patients with lower extremity traumatic injuries that are medically clear for physically ready for therapy and will receive a floor pedal bike with guided exercises at home.